RPX7009 and RPX2014

DRUG2 trials

Sponsors

Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company)

Conditions

Healthy SubjectsSubjects With Normal Renal FunctionSubjects With Varying Degrees of Renal Insufficiency and

Phase 1

The Safety and Pharmacokinetics of Carbavance™ (RPX2014/RPX7009) in Subjects With Renal Insufficiency

CompletedNCT02020434

Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company)Subjects With Normal Renal Function, Subjects With Varying Degrees of Renal Insufficiency and

Start: 2014-01-31End: 2014-10-31Updated: 2018-03-05

Evaluating the Plasma, Epithelial Lining, and Alveolar Macrophage Concentrations of Intravenous Carbavance™ (RPX2014/RPX7009) in Healthy Adult Subjects

CompletedNCT02073812

Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company)Healthy Subjects

Start: 2014-02-28End: 2014-04-30Updated: 2018-03-05

Related Papers

Single-Dose Pharmacokinetics and Safety of Meropenem-Vaborbactam in Subjects with Chronic Renal Impairment

Antimicrobial Agents and Chemotherapy2018-01-0548 citations